Figures & data
Figure 1 Patient reality when taking a drug. It is shown the different elements analyzed and taken into account by the interpretation software g-Nomic: Primary (PP) or secondary (SP) pathways, personal background genetics – Extensive (EM), Intermediate (IM), Ultra (UM), and Poor (PM) Metabolizers, drug–drug interactions, lifestyle, nutritional supplements inhibitors and inducers, and other risks.
Figure 2 g-Nomic pharmacogenetics report for aripiprazole of a patient showing a PM CYP2D6 phenotype.
Figure 3 g-Nomic pharmacogenetics report for a CYP2D6 PM individual prescribed with tamoxifen.
Figure 4 Drug interaction between simvastatin and ticagrelor: The two drugs are metabolized by CYP3A4.
Figure 5 Interpretion of g-Nomic in the case of drug–lifestyle interaction: Tamoxifen plus calcium.
Figure 6 g-Nomic report in the case of the prodrug inhibition caused by paroxetine on the formation of endoxifen from tamoxifen.
Figure 7 g-Nomic report in case of the drug induction of several cytochrome P-450 enzymes produced by Rifampin which may low plasma levels of drugs such as Paroxetine.
Figure 8 g-Nomic report showing risks associated with specific medications.
